Stock Movers: 3M Profit Outlook, Netflix-Warner Bros. Deal, GSK Acquires Rapt Therapeutics

3M's Profit Outlook and Performance

• 📉 3M's shares experienced a significant drop, as much as 5%, following a profit forecast that fell short of analyst expectations.
• 💡 Despite a 20% gain in the past 12 months, driven by operational revamps and new product pipelines, the company's momentum is showing signs of slowing.
• 🚀 Key growth areas like the electrical business targeting data centers for AI and positioning nuclear facilities for power demand helped in 2025, but the outlook indicates a deceleration.

Netflix's Amended Warner Bros. Deal

• 🎬 Netflix shares saw a slight increase, up over 1%, amidst news of an amended, all-cash agreement to acquire Warner Bros. Discovery's studio and streaming assets.
• 💰 This revised offer aims to expedite the sale process, with Netflix proposing a $30 per share cash tender.
• 🗓️ Netflix anticipates shareholders will be able to vote on the transaction by April, though the full process is expected to take considerable time.

GSK's Acquisition of Rapt Therapeutics

• 🤝 GSK has agreed to acquire the San Francisco-based biotech company Rapt Therapeutics for $2.2 billion.
• 💊 Rapt Therapeutics develops treatments for inflammatory and immunologic diseases, and the deal grants GSK global rights to potential new therapies.
• 🎯 The acquisition aligns with GSK's strategic focus to double down on oncology medicines and immunology/inflammatory drugs.
• 📈 The acquisition price represents a significant premium of 65% over Rapt Therapeutics' previous closing price.